Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Breast Cancer Research : BCR
|
July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Andreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 19, 2005
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer
Elisabeth Quoix, Jean-Luc Breton, Radj Gervais, et al.
The Oncologist
|
May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA
Sandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer
John R Eckardt, Joachim von Pawel, Zsolt Papai, et al.
Clinical Chemistry and Laboratory Medicine
|
December 29, 2024
Refining within-subject biological variation estimation using routine laboratory data: practical applications of the refineR algorithm
Eirik Åsen Røys, Kristin Viste, Christopher-John Farrell, et al.
Cancer Chemotherapy and Pharmacology
|
August 15, 2014
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
Amit Garg, Angelica Quartino, Jing Li, et al.
The Oncologist
|
March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
Sandra M Swain, Michael S Ewer, Javier Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R Eckardt, Joachim von Pawel, Jean-Louis Pujol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer
Rodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.
Clinical Chemistry
|
November 4, 2024
Estimating Reference Change Values Using Routine Patient Data: A Novel Pathology Database Approach
Eirik Åsen Røys, Kristin Viste, Ralf Kellmann, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Breast Cancer Research : BCR
|
July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Andreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 19, 2005
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer
Elisabeth Quoix, Jean-Luc Breton, Radj Gervais, et al.
The Oncologist
|
May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA
Sandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer
John R Eckardt, Joachim von Pawel, Zsolt Papai, et al.
Clinical Chemistry and Laboratory Medicine
|
December 29, 2024
Refining within-subject biological variation estimation using routine laboratory data: practical applications of the refineR algorithm
Eirik Åsen Røys, Kristin Viste, Christopher-John Farrell, et al.
Cancer Chemotherapy and Pharmacology
|
August 15, 2014
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
Amit Garg, Angelica Quartino, Jing Li, et al.
The Oncologist
|
March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
Sandra M Swain, Michael S Ewer, Javier Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R Eckardt, Joachim von Pawel, Jean-Louis Pujol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer
Rodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.
Clinical Chemistry
|
November 4, 2024
Estimating Reference Change Values Using Routine Patient Data: A Novel Pathology Database Approach
Eirik Åsen Røys, Kristin Viste, Ralf Kellmann, et al.
Page
of 4